TY - JOUR
T1 - Erratum :
T2 - Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs (Endocrine-Related Cancer DOI: 10.1530/ERC-24-0043)
AU - Araujo-Castro, Marta
AU - Biagetti, Betina
AU - Menéndez Torre, Edelmiro
AU - Novoa-Testa, Iria
AU - Cordido, Fernando
AU - Pascual-Corrales, Eider
AU - Rodríguez Berrocal, Víctor
AU - Guerrero-Pérez, Fernando
AU - Vicente, Almudena
AU - Percovich, Juan Carlos
AU - García-Centeno, Rogelio
AU - González-Fernández, Laura
AU - Ollero García, María Dolores
AU - Irigaray Echarri, Ana
AU - Moure Rodríguez, María Dolores
AU - Novo-Rodríguez, Cristina
AU - Calatayud, María
AU - Villar-Taibo, Rocío
AU - Bernabéu, Ignacio
AU - Alvarez-Escola, Cristina
AU - Benítez Valderrama, Pamela
AU - Tenorio Jiménez, Carmen
AU - Abellán-Galiana, Pablo
AU - Venegas, Eva
AU - González-Molero, Inmaculada
AU - Iglesias, Pedro
AU - Blanco Carrera, Concepción
AU - Vidal-Ostos De Lara, Fernando
AU - de Miguel Novoa, Paz
AU - López-Mezquita, Elena Teresa
AU - Hanzu, Felicia A.
AU - Aldecoa, Iban
AU - Aznar, Silvia
AU - Lamas, Cristina
AU - Aulinas, Anna
AU - Asla Roca, Queralt
AU - Gracia Gimeno, Paola
AU - Recio-Córdova, José María
AU - Avilés-Pérez, María Dolores
AU - Asensio-Wandosell, Diego
AU - Sampedro-Núñez, Miguel
AU - Cámara, Rosa
AU - Paja Fano, Miguel
AU - Ruz-Caracuel, Ignacio
AU - Fajardo-Montañana, Carmen
AU - Marazuela, Mónica
AU - Puig Domingo, Manuel
PY - 2024
Y1 - 2024
N2 - The authors and journal apologise for an error in the above paper, which appeared in volume 31 part 7, article ID e240043. The error relates to a sentence in the Results section given on page 6. The sentence stated: "Twenty-three patients treated with pegvisomant developed secondary side effects: lipohypertrophy in 11, transaminases elevation in 2, asthenia in 2, abdominal discomfort in 2, hair loss in 1, and headache in 1." This should have stated: "Nineteen patients treated with pegvisomant developed secondary side effects: lipohypertrophy in 11, transaminases elevation in 2, asthenia in 2, abdominal discomfort in 2, hair loss in 1, and headache in 1." The Version of Record has been corrected online.
AB - The authors and journal apologise for an error in the above paper, which appeared in volume 31 part 7, article ID e240043. The error relates to a sentence in the Results section given on page 6. The sentence stated: "Twenty-three patients treated with pegvisomant developed secondary side effects: lipohypertrophy in 11, transaminases elevation in 2, asthenia in 2, abdominal discomfort in 2, hair loss in 1, and headache in 1." This should have stated: "Nineteen patients treated with pegvisomant developed secondary side effects: lipohypertrophy in 11, transaminases elevation in 2, asthenia in 2, abdominal discomfort in 2, hair loss in 1, and headache in 1." The Version of Record has been corrected online.
U2 - 10.1530/ERC-24-0043e
DO - 10.1530/ERC-24-0043e
M3 - Article
C2 - 39059428
SN - 1351-0088
VL - 31
JO - Endocrine-Related Cancer
JF - Endocrine-Related Cancer
IS - 9
ER -
SDG 3 Good Health and Well-being